Core Insights - GRI Bio, Inc. is advancing a pipeline of Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company will present its research on the inactivation of iNKT cells and its effects on fibroblast activation and fibrosis at the 2025 ATS International Conference [2] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory, fibrotic, and autoimmune diseases [3] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [3]
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference